UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/717,182	11/18/2003	Michel Xilinas	9357-029-999	5994
20583 JONES DAY	7590 03/26/200	EXAMINER		
222 EAST 41S			CARTER, KENDRA D	
NEW YORK, NY 10017			ART UNIT	PAPER NUMBER
			1617	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
31 DAYS		03/26/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)		
Office Action Summary		10/717,182	XILINAS ET AL.		
		Examiner	Art Unit		
		Kendra D. Carter	1617		
The MAILING DATE of thi Period for Reply	s communication app	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
• • • • • • • • • • • • • • • • • • • •	2b)⊠ This condition for allowar	ovember 2003. action is non-final. ace except for formal matters, profix parte Quayle, 1935 C.D. 11, 45			
Disposition of Claims					
4)	is/are withdrav wed. cted. ected to.	vn from consideration.			
Application Papers					
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ★ All b) ★ Some * c) ★ None of:  1. ← Certified copies of the priority documents have been received.  2. ★ Certified copies of the priority documents have been received in Application No. 09485909.  3. ← Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawii  3) Information Disclosure Statement(s) (F	ng Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte		

Page 2

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 6, 13, and 42-63, are drawn to a pharmaceutical composition comprising phanquinone and a compound or a mixture of compounds, selected from the group comprising antioxidants, acetylcholine enhancers, trace metals, prosthetic groups and clioquinol provided, when clioquinol is selected, that at least one further compound is selected from the said group, classified in class 424, subclasses 451, 449, 464, and 600 for example.

II. Claim 64, is drawn to a kit comprising in one or more containers an amount of phanquinone and clioquinol effective to treat or prevent Alzheimer's disease, and an amount of vitamin B<sub>12</sub> effective to inhibit a detrimental side effect of clioquinol administration, classified in class D42, subclasses 100-104 and 108 for example.

The inventions are independent or distinct, each from the other because:

Inventions of Group I and Group II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have

Art Unit: 1617

different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the inventions of Group I can be in a kit that does not comprise cliquinol or a vitamin.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

## Species Election

This application contains claims directed to the following patentably distinct species:

- 1) antioxidants
- 2) acetylcholine enhancers
- 3) trace metals
- 4) prosthetic groups.

The species are independent or distinct because each species are made up of compounds with different structures that can be classified in various classes and subclasses.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the

election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection

under 35 U.S.C.103(a) of the other invention.

During a telephone conversation with Zhu Xiachun on March 13, 2007 a request for an oral election to the above restriction requirement was made, but a written restriction was requested.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kendra D. Carter whose telephone number is (571) 272-9034. The examiner can normally be reached on 8:30 am - 5:00 pm.

Application/Control Number: 10/717,182 Page 6

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**KDC** 

SPEENI PATTATENT EXAMINER